论文标题
间充质干细胞作为载体细胞，以实现有效的肿瘤病毒内肿瘤内递送进行溶瘤病毒疗法：系统评价
Mesenchymal stem cells as carrier cells to enable effective intratumoral delivery of oncolytic virus for oncolytic virotherapy: a systematic review
论文作者
论文摘要
溶瘤病毒可能是自然发生或遗传工程的，是一种优先感染和破坏癌细胞的病毒。由于它们的选择性，它们的表现要优于常规化学疗法和放疗，这两者都有影响非目标细胞并引起不良不良副作用的趋势。溶瘤病毒疗法是一种癌症治疗，其中故意将癌病毒引入受癌症影响的患者中，以便他们在本地或系统上以类似于化学疗法的方式感染和破坏癌细胞，但具有更大程度的选择性。多项研究表明，溶瘤病毒疗法在体外是有效的，但由于方法的主要局限性，体内的发现仍然模棱两可：效率低下的治疗剂递送到其靶标，这受到免疫系统的影响很大。在这里，我们提出通过利用最近在癌症研究中的发现来克服这一局限性：载体细胞。通过利用其肿瘤促进活性，可以通过用作癌性病毒朝向其靶标的携带者来用于癌症治疗中充质干细胞。这种方法直接解决了常规的溶瘤病毒疗法的局限性，在系统给药后，溶瘤病毒通常递送很差。
Oncolytic viruses, which may be naturally occurring or genetically engineered, are a type of virus that infects and destroy cancer cells preferentially. Owing to their selectivity, they outperform conventional chemotherapy and radiotherapy, which both have a tendency to impact non-target cells and cause unwanted adverse side effects. Oncolytic virotherapy is a type of cancer treatment in which oncolytic viruses are deliberately introduced into patients affected with cancers in order for them to infect and destroy cancer cells locally or systemically, in a manner analogous to chemotherapy but with a greater degree of selectivity. Multiple studies indicate that oncolytic virotherapy is effective in vitro but in vivo findings remain ambiguous due to the approach's primary limitation: inefficient therapeutic agent delivery to its target, which is heavily influenced by the immune system. Here, we propose overcoming this limitation by exploiting a recent discovery in cancer research: a carrier cell. By exploiting their tumor-promoting activities, mesenchymal stem cells may be employed for cancer therapy by serving as a carrier for the oncolytic viruses toward their target. This approach directly addresses the limitation of conventional oncolytic virotherapy, where oncolytic viruses are often poorly delivered after systemic administration.
